PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
2.53%
Growth of 2.53% versus flat Medical - Pharmaceuticals revenue. Walter Schloss would verify growth quality.
2.00%
Cost increase while Medical - Pharmaceuticals shows cost reduction. Peter Lynch would examine competitive disadvantages.
4.70%
Positive growth while Medical - Pharmaceuticals median is negative. Peter Lynch would examine competitive advantages.
2.12%
Margin change of 2.12% versus flat Medical - Pharmaceuticals margins. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
G&A reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate efficiency gains.
-100.00%
Marketing expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive implications.
-11.20%
Other expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
0.98%
Operating expenses growth while Medical - Pharmaceuticals reduces costs. Peter Lynch would examine differences.
1.84%
Total costs growth while Medical - Pharmaceuticals reduces costs. Peter Lynch would examine differences.
-7.14%
Interest expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
-4.46%
D&A reduction while Medical - Pharmaceuticals median is 0.21%. Seth Klarman would investigate efficiency.
20.59%
EBITDA growth exceeding 1.5x Medical - Pharmaceuticals median of 6.17%. Joel Greenblatt would investigate advantages.
17.61%
EBITDA margin growth exceeding 1.5x Medical - Pharmaceuticals median of 1.96%. Joel Greenblatt would investigate advantages.
19.88%
Operating income growth exceeding 1.5x Medical - Pharmaceuticals median of 0.42%. Joel Greenblatt would investigate advantages.
16.92%
Operating margin growth exceeding 1.5x Medical - Pharmaceuticals median of 0.42%. Joel Greenblatt would investigate advantages.
367.07%
Other expenses growth exceeding 1.5x Medical - Pharmaceuticals median of 11.99%. Jim Chanos would check for issues.
33.70%
Pre-tax income growth exceeding 1.5x Medical - Pharmaceuticals median of 3.32%. Joel Greenblatt would investigate advantages.
30.39%
Pre-tax margin growth exceeding 1.5x Medical - Pharmaceuticals median of 1.69%. Joel Greenblatt would investigate advantages.
125.78%
Tax expense change of 125.78% versus flat Medical - Pharmaceuticals. Walter Schloss would verify strategy.
11.98%
Net income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
9.21%
Margin change of 9.21% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
11.99%
EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 1.53%. Joel Greenblatt would investigate advantages.
11.99%
Diluted EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 1.53%. Joel Greenblatt would investigate advantages.
-0.00%
Share count reduction while Medical - Pharmaceuticals median is 0.23%. Seth Klarman would investigate strategy.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.21%. Seth Klarman would investigate strategy.